Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business changes for 2025.
Edwards Lifesciences Corp (EW) Posted 70.82% Profit Margin Last Year—Can It Hold Up?
Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.13 which represents a decrease of $-1.43 or -1.97% from the prior close of $72.56. The stock opened at $72.5 and touched a low of $71.
Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
11 Analysts Have This To Say About Edwards Lifesciences
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Wolfe Research Issues Underperform Rating for Edwards Lifesciences Corp (EW) Stock
Wolfe Research has recently reduced Edwards Lifesciences Corp (EW) stock to Underperform rating, as announced on January 16, 2025, according to Finviz. Earlier, on December 16, 2024, BofA Securities had raised the stock from a Neutral to Buy.
Edwards Lifesciences upped to Buy at Stifel on TAVR growth
Edwards Lifesciences (NYSE:EW) traded higher on Thursday after Stifel upgraded the heart device maker to Buy from Hold, citing a turnaround in its position in the market for transcatheter aortic valve replacement (TAVR).
Stifel Upgrades Edwards Lifesciences (EW)
Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy. Analyst Price Forecast Suggests 12.29% Upside As of January 28, 2025, the average one-year price target for Edwards Lifesciences is $79.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...
Edwards Lifesciences upgraded to Buy from Hold at Stifel
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Orange County Business Journal4d
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...
Forbes2d
Edwards Lifesciences
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
Yahoo Finance3d
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for
Edwards Lifesciences (EW) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Geneos Wealth Management Inc. Decreases Stake in Edwards Lifesciences Co. (NYSE:EW)
Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...
Business Wire6d
EDWARDS LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Edwards Li…
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...
LPA Design Studios Wins California Green Building Award for Sustainable Design
LPA Design Studios' design for the expansion of Edwards Lifesciences' Irvine, California, campus has received the prestigious California Green Building Award for Merit from the U.S. Green Building ...